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      Nitric oxide (NO) is a pleiotropic molecule that is 
needed for physiological functions, especially in the 
brain NO induces vasodilatation, inhibits apoptosis 
and plays an important role in memory processes. A 
population of interneurons has been distinguished in 
the striatum by nicotinamide adenine dinucleotide 
phosphate-diaphorase (NADPH-d) staining, an 
enzyme that is identical with NO synthase (NOS). 
These interneurons are aspiny cells with dendritic 
branches and axonal arborisation extending to form a 
wide field. Single action  potentials  in these cells produce
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large inhibitory postsynaptic currents in medium-sized spiny neurons. Release 
of NO from these neurons facilitates the concurrent release of dopamine and 
glutamate (GLU). Although the influence of NOS-positive interneurons on 
striatal neuronal activity remains to be thoroughly characterized, evidence has 
accumulated suggesting that NO signaling may mediate and/or regulate 
multiple aspects of striatal neurotransmission.  
 Striatal NO signaling has a major impact on the responsiveness of 
dopaminergic (DA) neurons to electrical stimulation of the striatum and to 
some extent, the prefrontal cortex. Moreover, it is likely that NO signaling 
plays an important role in regulating the activity of striatal output neurons. 
Thus, striatal NOS interneurons may be critically involved in integrating 
corticostriatal sensorimotor information within striatal networks and 
synchronizing the activity of functionally related striatonigral sub-systems. 
 Our studies showed that systemic injections of the inhibitors of NOS 
decrease either elevate plus maze exploration or rearing in an open field 
arena. These results may involve motor effects of these compounds, since 
inhibitors of NOS induced catalepsy in mice. This effect was also found in rats 
after systemic, intracebroventricular or intrastriatal administration. Chronic 
NO synthesis inhibition induces plastic changes in NO producing neurons in 
areas related to motor control. In the same way, the application of NOS 
inhibitor twice a day, during four days caused cross-tolerance to the cataleptic 
effect of haloperidol. This raises the possibility that such treatments could 
decrease motor side effects associated with antipsychotic medications.  
 However, NO can be harmful mainly under oxidative stress conditions due 
to the oxidation and nitrotyrosilation of functional proteins. Considerable 
existing evidences indicate a role for NO–DA interactions in pathophysiological 
conditions such as Parkinson's disease (PD) and schizophrenia. However, the 
findings on the impact of nitrergic mechanisms in schizophrenia and PD are 
contradictory. In addition, the slow progression of these diseases, complicates 
experimental approaches to modeling their pathophysiological mechanism. 
Inducing experimental Parkinson in rats we found an interaction between NO 
system and neurodegenerative processes in the nigrostriatal pathway. Because 
NOS is an enzyme widely distributed and involved in a plethora of necessary 
physiological responses inside and outside the brain, the role of NO in human 
neurodegenerative disease is not as easily understood. 
 
Introduction 
 In 1664 anatomist Thomas Willis termed a prominent subcortical region of 
the telencephalon corpus striatum. Neuronal tracing techniques developed by 
Nauta and colleagues in the mid-1950s allowed for elucidation of connectivity 
of the broadly defined corpus striatal region, and the term basal ganglia was 
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adopted to refer to a collection of nuclei deep within the cerebrum. These 
nuclei include the caudate, the nucleus accumbens and the putamen – which 
are collectively called the striatum, and also the globus pallidus, the 
subthalamic nucleus and the substantia nigra (pars compacta and reticulata). 
Heimer and colleagues subsequently adopted the term ventral striatum to 
delineate the most ventral aspects of the striatum (i.e., nucleus accumbens and 
portions of the olfactory tubercle) from more dorsal regions (i.e., caudate 
nucleus or dorsal striatum). Thus, the core structures of the mammalian basal 
ganglia include the dorsal striatum, the ventral striatum, and the globus 
pallidus. Other nuclei, such as the central complex of the thalamus or the 
pedunculopontine nucleus and the ventral tegmental area also play a major role 
in basal ganglia functioning [1-3].  
 
The basal ganglia 
 The basal ganglia receive inputs from the neocortex and project massively to 
thalamic nuclei, which in turn project to the frontal cortex (corticocortical loop) 
[4]. Striatal information is transferred also to the pars reticulata of the substantia 
nigra which projects to the medial part of the thalamus complex (the parafascicular 
nucleus), going back to the caudate nucleus (Nauta-Mehler's loop) [5]. The globus 
pallidus internal segment neurons provide inhibitory inputs to the thalamus, the 
pedunculopontine nuclei and the superior colliculus. The subthalamic nucleus 
(corpus Luysi) is a relatively small nucleus located ventrally to the zona incerta and 
dorsally to the cerebral peduncle, is a relay nucleus controlling pallidal function 
[6]. The human substantia nigra pars compacta is a melanin-rich structure located 
dorsal to the pyramidal tracts (crus cerebri) in the midbrain. The pedunculopontine 
nuclei have prominent projections to the basal ganglia, mainly the pars compacta 
of the substantia nigra and the subthalamic nucleus.  
 The brain stem input to the striatum (dorsal and ventral) and, to a lesser 
degree, the globus pallidus and subthalamic nucleus is primarily from the DAergic 
cell groups in the ventral tegmental area (A10), substantia nigra (A9), and 
retrorubral area. The axons of these neurons run along the medial forebrain bundle 
to reach the dorsal striatum (the nigrostriatal pathway). The substantia nigra pars 
reticulata neurons send inputs to the pedunculopontine nuclei. The ventral part of 
the striatum also receives a prominent projection from the amygdala [2,3]. 
 Although they are highly complex, the anatomical connections have been 
schematized in block diagrams in order to test specific hypotheses. Basically, there 
are three distinct pathways from striatum to thalamus, of primary importance, 
named the direct, the indirect and the hyperdirect pathways (Figure 1). The direct   
pathway is inhibitory and passes monosynaptically from the striatum to the globus 
pallidus internal segment. The indirect pathway reaches the same destination but 
synapses  first in  the external  segment of  the globus  pallidus  and      then      in the  
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Figure 1. A schematic diagram of the cortico-STN-GPi/SNr hyperdirect, corticostriato-
GPi/SNr direct and cortico-striato-GPe-STN-GPi/SNr indirect pathways. Open and 
filled arrows represent excitatory GLUergic and inhibitory GABAergic projections, 
respectively. Cx cerebral cortex; GPe external segment of the globus pallidus; GPi 
internal segment of the globus pallidus; SNr substantia nigra pars reticulata; STN 
subthalamic nucleus; Str striatum; Th thalamus [modified from 7]. 
 
subthalamic nucleus. Recently there has been growing evidence of a direct cortico–
subthalamic nucleus–pallidal pathway described as hyperdirect pathway [7,8]. 
 Interaction between these pathways has not yet been fully elucidated. 
Activation of the direct pathway has an excitatory effect on the thalamocortical 
projection, which results in a production of movement or different behaviors. 
Activation of the indirect pathway leads to an activation of the subthalamic nucleus 
and then to an increased inhibition of the thalamocortical projection. The 
hyperdirect pathway conveys powerful excitatory effects from the motor-related 
cortical areas to the pallidum, bypassing the striatum, with shorter conduction time 
than effects conveyed through the direct and indirect pathway. The competing 
pathways act like the brake and accelerator in a car. The brake–accelerator model 
suggests that release (disinhibition) of the thalamus by the direct pathway is 
opposed by the indirect pathway. The signals through the hyperdirect pathway may 
inhibit motor programs widely, and then the signals through the direct pathway 
may adjust the selected motor program according to the situation [4,6-8]. 
 This anatomy means the basal ganglia are in a prime position to influence 
the executive functions of the forebrain. Through their extensive cortical 
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connections, the basal ganglia can influence both motor and cognitive 
functions [2-3,9]. There has been increasing evidence for the involvement of 
the basal ganglia in behavioral syndromes [10,11].  
 Striatal neurons consist mainly (96%) of medium-sized densely spiny 
neurons (cell body 20-25 µm in diameter) from which radiate branched spherical 
dendritic arborization densely laden with spines [12,13]. Their axon gives rise to 
a dense local collateral arborization, which contacts other spiny neurons. The 
dendritic arbors extend in a domain approximately 150-250µm in diameter such 
that neighboring neurons share common inputs. The medium spiny neurons use 
GABA as its neurotransmitter and also contain neuropeptides, some substance P 
and dynorphyn, whereas others contain enkephalin. The dendrites express 
receptors for numerous other neurotransmitters.  
 Spiny neurons are silent in the rest condition and discharge when they 
receive an input from an active cortical region. Pyramidal cortical neurons 
located primarily in layer 5 (also some in layers 2, 3 and 6), provide inputs to 
striatum. These inputs utilize the amino acid GLU as a neurotransmitter. 
Cortical and thalamic excitatory inputs make asymmetric synaptic contact 
mainly with the heads of the spines. Input from the substantia nigra pars 
compacta, the thalamus, or other intrinsic striatal neurons contact the dendritic 
shafts. DA fibers from the midbrain cell groups make symmetric synaptic 
contact primarily with the necks of dendritic spines and on the interspine 
dendritic shafts. The latter input is, therefore, in crucial position to modulate or 
inhibit cortical input [1-3].  
 The activity of individual and ensembles of medium-sized spiny neurons is 
also dependent upon local axon collaterals of other medium-seized neurons or 
from striatal interneurons whose axons do not exit the striatum. Interneurons 
comprise about 10% of the neostriatal GABAergic neuron population. 
GABAergic interneurons establish contacts with the dendritic shaft of 
neighboring spiny neurons, thus providing, in addition to the local collateral 
arborization of spiny neurons, the structural basis for a local surrounding 
inhibition. Among the neurons that have been clearly identified in this class are 
(i) the large aspiny or spidery neurons that utilize acetylcholine as a transmitter 
(2%, containing choline acetyltransferase) and, (ii) several types of aspiny 
neurons, which include those that contain either somatostatin and neuropeptide 
Y or somatostatin and NOS/NADPH-d.  
 The striosome and matrix compartments of the striatum are vividly 
demarcated by their differential expression of neurotransmitter-related 
compounds ranging from second messengers to neurotransmitters, neuropeptides, 
and  their receptors [14]. The  different  connections  of  striosomes  and   matrix 
suggest that they participate differentially in limbic-based (striosome) and 
sensorimotor/associative (matrix) forebrain circuits. Further        on, sriatal medium 
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spiny neurons are segregated into separate populations that form the basis of 
the striosomes or patches and matrix (80% of the striatum) compartments, 
whose connections are related to the laminar and regional organization of the 
cortex. Cortical afferents form synapses on the cell body and proximal 
dendrites of somatostatin-neuropeptide Y–NOS-containing interneurons. 
Striatal interneurons, including cholinergic and NOS neurons, are largely 
confined to the borders of the striosomes and the matrix, but their dendrites 
and axonal fields ignore compartmental boundaries. Given this preferential 
localization, cholinergic and NOS neurons are believed to mediate interactions 
between striatal projection neurons of both compartments.  
 
A brief history of and introduction to physiological 
and pathological role of nitric oxide in the striatum  
 NITRIC OXIDE (NO) is a poisonous, unstable gas that has been known 
for years to be a constituent of car fumes, probably involved in depletion of the 
ozone layer. Drugs that release NO, such as nitroprusside and nitroglycerines, 
have been used successfully in cases of angina pectoris and other blood-supply 
problems. Alfred Nobel, who invented nitroglycerine, was prescribed the drug 
himself to support his ailing heart.  
 NO is a neurotransmitter that is synthesized from L-arginine by three 
isoforms of NOS: constitutive neuronal (nNOS, NOS-1), endothelial (eNOS, 
NOS-3), and inducible (iNOS, NOS-2). In the brain, the 160kDa nNOS is the 
predominant splice variant, and contains an N-terminal PSD/Discs-large/ZO-1 
homologous (PDZ)-binding domain, which anchors this complex to the 
postsynaptic density in the vicinity of the N-methyl-D-aspartate type-glutamate 
receptor (NMDAR). The PDZ domain of nNOS binds to a similar PDZ domain 
from the postsynaptic density protein, PSD-95, which in turn binds to the 
cytosolic tail of the NMDAR [15]. These molecular interactions explain how 
Ca2+ influx through NMDA receptors is efficiently coupled to NO synthesis 
and activity. Following its synthesis at postsynaptic site NO may diffuse back 
to the presynaptic terminal and increase guanosine 3', 5'-monophosphate 
(cGMP) levels through activation of soluble guanylate cyclase (GC). The same 
cerebral neurons stain for NOS and NADPH-d, and purified brain NOS has 
NADPH-d activity (see Figure 2). Systemic application of L-arginine analogues 
such as NG-nitro-L-arginine (LNOARG) has been shown to produce an in vivo 
and in vitro time-dependent irreversible inhibition of brain NOS [14] (Figure 2). 
 Inhibition of NOS in rodents may modify many brain physiological and/or 
pathological conditions as such synaptic plasticity [16,17], neurotransmitter 
release  [18], regulation  of  gene expression, reduction  on basal motor activity 
[19,20] (Figure 5) and either degenerative (Parkinson, Huntington) or 
neuropsychiatric (schizophrenia) diseases [21-24]. 








Figure 2. Biosynthetic pathway of NO in neurons catalyzed by the nNOS 
dependent on calcium and calmodulim. NMDA receptors are coupled to nNOS 
through a PSD95 multimer. NMDA receptor-modulated calcium influx results in an 
increased catalytic activity of nNOS mediate by PDZ domains/PSD95 interaction. 
Oxidation of one of the guanidino nitrogens of L-arginine, and its intermediate leads to 
the formation of L-citrulline and NO. All NOS isoforms are homodimeric enzymes that 
depend on the substrate L-arginine as well as on the cofactors/coenzymes nicotinamide 
adenine dinucleotide phosphate (NADPH), tetrahydrobiopterin (BH4), flavin adenine 
dinucleotide (FAD), flavine mononucleotide (FMN), oxygen (O2) and protoporphyrin 
IX. The presence of heme, BH4 and L-arginine promotes dimer formation and 
stabilization. NOS dimerisation is crucial for catalysis because each reductase domain 
transfers NADPH-derived electrons to the heme located in the adjacent subunit, 
whereas, electron transfer between reductase and oxygenase domains on the same 
subunit does not occur. 
 
 NOS/NADPH-d activity was associated with functional properties of 
extrapyramidal areas. Vincent and Kimura [25], using NADPH-d 
histochemical technique, demonstrated that NOS is present in not only DA 
terminal regions such as the striatum medium spiny neurons and nucleus 
accumbens, but also in the site of origin of DA cells, in the substantia nigra 
pars compacta and ventral tegmental area (Figure 3).  
 NOS-positive interneurones representing 1–2% of striatal neurons are 
aspiny  cells of  12–25 µM in diameter with fusiform   or polygonal somata. The 
axonal arborisation extends to form a wider field (1000 µm). Within the striatal 
complex, neuronal  NOS activity is  primarily  responsible for the generation of 




Figure 3. Double labeling of nNOS and TH in the Striatum and Substantia nigra in the 
rat brain. Confocal micrography (A-C, Leyka SP5) of double-staining labeling using TH 
and nNOS immunohystochemistry in the striatum (A-C) and substantia nigra (D) of the rat 
brain. NOS (A), is labeled in red and TH (B), is labeled in green; C and D are representative 
micrographys of the simultaneous visualization of DA and NO innervation in brain regions. 
D: Double-stained sections were analyzed using fluorescence microscopy (Nikon, Japan). 
The close proximity of nNOS (red) and TH (green) neurons and fibers immunopositive 
reaction in the striatum and substantia nigra (D) gives hysthochemical support for interaction 
between DAergic and NOS neurotransmission. 
 
NO and is localized exclusively to a subclass of aspiny interneurons that 
colocalize somatostatin, neuropeptide Y, and GABA [26,27]. 
 
Nitric oxide and dopamine in the striatum 
 NO generation is critically involved in mediating electrotonic coupling 
between medium spiny neurons [28]. NMDA receptor stimulation both in vivo and 
in vitro modulates the striatal release of DA [29,30]. NOS interneurons are 
profoundly influenced by the level of DAergic activity [31-35]. Striatal 
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interneurons have been shown to receive synaptic input from tyrosine hydroxilase 
immunopositive processes [34] and corticostriatal boutons [35]. In neurochemical 
studies aimed at examining the impact of exogenous NO on striatal DA 
neurotransmission, the most consistent effect is a facilitatory influence. 
Endogenous NO enhances DA efflux in the striatum through the elevation of 
GLUergic tone [36]. NO-generating agents increase striatal DA efflux or inhibit its 
reuptake both in vitro [37] and in vivo [31]. Given the proximity of glutamatergic 
and DAergic (Figure 3) inputs on the NOS interneuron dendrites [34,38], it is 
likely that these afferents interact via presynaptic and/or postsynaptic mechanisms 
to regulate striatal NOS activity [39]. In particular, the release of NO might 
modulate the activity of other striatal cells over a wide area.  
 A role for striatal NO in modulating inhibitory GABAergic striatonigral 
systems first was reported by Greengard and colleagues [40] in a study 
demonstrating that sodium nitroprusside activates guanylyl cyclase in 
striatonigral terminals leading to the enhancement of cGMP-dependent protein 
kinases phosphorylation of DA and cyclic AMP-regulated phosphoprotein 
(DARPP-32) [40]. Ultrastructural studies of striatal NOS-containing 
interneurons have reported that NOS-containing terminals synapse on dual-
input dendritic spines of striatal medium spiny neurons known to contain high 
levels of Guanilate Cyclase, cGMP-dependent protein kinase and other 
components of the cGMP signaling system [41, 43, 38]. The NO/cGMP 
pathway recently has been shown to be critically involved in the induction of 
long-term depression of excitatory postsynaptic potentials in striatal spiny 
neurons produced after high-frequency stimulation of corticostriatal pathways 
[43]. In addition, NOS-positive cells might control local blood flow in the 
striatum by releasing NO acting directly on guanylate cyclase in the vascular 
smooth-muscle and causing vasodilatation [44]. 
 
NO: Integration of striatal convergent motor information? 
 NO generated as a consequence of activation of corticostriatal pathways 
may be involved in regulating the activity of striatal local circuit and projection 
neurons and/or their respective afferents inputs. NO might also act as a 
transmitter to affect striatal activity, either through direct interactions with 
ligand-gated channels or by influencing, through the stimulation of second 
messenger systems, surrounding striatal projecting neurons. Although the 
influence of NO on striatal neuronal activity remains to be thoroughly 
characterized, evidence has accumulated suggesting that NO may participate in 
the integration of convergent motor information within striatal networks.  
 Modulation of nNOS activity by multiple signaling cascades permits the 
regulated production of NO in response to neuronal stimulation because NO 
cannot be stored in synaptic vesicles like other neurotransmitters. Non-specific 
subtotal NOS-inhibition reduced exploratory activity decreased the open arm 
B 
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exploration of an elevated plus maze [45-47] accompanied by a decrease in the 
number of enclosed arm entries, a measure related to general exploratory 
activity in this test. In the open field test LNOARG and 7Nitroindazole (7NIO) 
[48], a selective neuronal NOS inhibitor, decreased exploratory behavior 
[45,49-51]  (Figure 4). Rats and mice treated with various NOS inhibitors 
show problems with fine motor control [51-55]. Thus, behavioral studies have 
demonstrated  that  pharmacological  blockade of  NO signaling decreases basal 
locomotor activity [20] and behaviors induced by substance P, D1 and D2 
agonists [56-59], NMDA receptor antagonists [60].  
 The effect of NOS inhibition on movement coordination function can be 
measured by the footprint pattern test (Figure 5). It analyzes complex 
movements during locomotion by taking into account limb position or gait 
patterns [63-65]. In this test standing support seems to be related to the 
integrity of the propriospinal system, controlled by both descending and 
segmental afferent input [61]. Drugs that produce ataxia in humans, such as 
ethanol or diazepam, decrease  locomotor  and  rearing activity in rats [66] and 
induce deficits in coordinated hind limb movements [67]. Rats tested while 
walking under LNOARG treatment do not show any modification in their 
locomotion pattern [51] (Figure 6). In contrast, haloperidol treatment results in 
a significant doses dependent  increase in the animal’s base of support (DBL in 
Figure 7) and  a significant       decrease in the animal’s right and left (RSL/LSL in 
Figure 7) Therefore, the reduced exploratory activity induced by LNOARG do 
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Figure 4. Effects of a single 7NIO or vehicle (Veh) treatment on exploratory 
behavior of mice tested in an open field. Animals received a single 7NIO (3-30 
mg/kg) or vehicle (Veh) injection and the number of squares crossed (right side, 
hatched bars) and rearings (left side, open bars) were recorded. 
Physiology and pathology of nitric oxide in the striatum  139 
 
 
Figure 5. Reconstruction of the hind paw prints illustrating the measurements 
used. Base of support (DBF), right (RSL) and left (LSL) stride length were measured 
from the prints. Figure is based on Kunkel-Bagden [61] with modifications. The 
animal’s fore-and hindpaws were inked and footprints were made on paper covering a 
confined walkway wooden platform (15cm wide by 45 cm long) with a dark shelter. 
The paper was saturated with bromophenol blue, wich changes from orange to dark 
blue when contacted with moisturized hindfeet of the rat [62]. The forepaw prints were 
used to standardize the direction of locomotion. Three steps were used to determine the 
locomotion pattern. The base support  was determined by measuring the core to core 
distance between the central pads of the hindfeet. Stride length was measured between 
the central pads of two consecutive prints on each side does not relate to any gross 
impairment of locomotion pattern. 
 
 In contrast, neuronal NOS (nNOS) knockout mice have no grossly evident 
defects in locomotor activity [68]. However, the studies were all conducted 
during the day (between 14:00 and 16:00, lights on at 07:00). Krigsfield et al 
[69] reported striking, discrete abnormalities in balance and motor coordination 
in nNOS knockout mice reflected selectively at night. Furthermore, eNOS          
knockout knockout mice were hypoactive during the first exposure to the open 
field test [70] and show improved motor-coordination [71]. Those observations 
suggest that eNOS-derived NO might be involved in the control of general 
activity [70,72] or the motivation to explore novel environments. A possible 
hypothesis is eNOS and nNOS might be functional antagonists in regulating 
motor coordination and balance.  
 There are several important distinctions of acute experiments using NOS 
inhibitors (lasting hours) from experiments involving genetically altered mice. 
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Figure 6. Footprint analysis of rats 2 hs after receiving LNOARG or saline. None 
of the LNOARG doses significantly modified the spontaneous walking of the mice. The 
mean (+SEM) distances for controls and animals which received LNOARG (10-

























Figure 7. Rats base of support and stride length measured from the footprints after 
haloperidol treatment. The distance between the central pads of the hind paws increased after 
haloperidol 2 mg/kg treatment when compared with haloperidol 1mg/kg (DBL, t18=-2,53, 
p=0,021). The stride length decreased in group haloperidol 2mg/kg as compared with group 
saline (RLS, F2,27=8,06, p<0,001; LSL F2,27=8,4, p<0.001). The mean (+SEM) distances for 
controls and animals which received Haloperidol are presented. Asterisk indicates significant 
difference from sal. Double asterisk indicate difference from Hal 1mg/kg. 
 
In addition findings in acute experiments may be quite different from those of 
chronic NO depletion states. A caveat with the use of knockout models is the 
possibility of undefined effects and adaptations secondary to the targeted gene 
[73]. Mice lacking NOS throughout embryonic development may present 
structural changes and changes in other mediators and processes that may 
induce compensatory increases in other mediators or functions. For example, 
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on the basis of the blocking effects of LNAME, NO was thought to be an 
essential retrograde messenger in postsynaptic neurons that feed back to 
postsynaptic neurons for long- term potentiation. Surprisingly, long term 
potentiation was not affected in nNOS and eNOS knockout animals. On the 
other hand, long-term potentiation was abolished in nNOS and eNOS double-
knockout animals [74]. In addition, the striatum of nNOS knockout mice 
displays only about a 50% loss in nNOS positive neuronal cells [75,69]; by 
contrast, cerebellar and amygdala staining is abolished. Conceivably, residual 
nNOS, which is prominent in areas such as the cerebral cortex and striatum, 
protects nNOS knockout mice from more extensive abnormalities. 
 
Basal ganglia: Neurologic and neuropsychiatric disorders 
 In the early 1900, Kinnier-Wilson coined the term extrapyramidal system 
to describe the basal ganglia system that interacts with brain-stem structures 
independently from the pyramidal tract to influence motor behavior [76]. He 
conceived of the term the extrapyramidal system refers to the basal ganglia 
with their anatomical connections, and extrapyramidal disorders are hypokinetic 
and hyperkinetic states that ensue from lesions in these anatomical sites. 
Wilson's emphasis on the role of the basal ganglia in motor behavior was 
driven by his early discoveries revealing motor disorders in humans following 
damage to this brain region [76].  
 Many common neurological and psychiatric disorders, such as PD, 
attention deficit-hyperactivity disorder, Huntington’s disease, and Tourette 
syndrome are primarily due to basal ganglia dysfunction, and many other 
diseases such as schizophrenia and drug addiction have a large basal ganglia 
component. There is growing evidence to support a role for NO in the etiology 
of neurologic conditions including chronic neurodegenerative diseases. The 
medium spiny neurons are among the first neurons to degenerate during the 
development of Huntington's chorea [77]. The poverty of movement in PD 
results from over-activity of the indirect pathway, whereas excess movement 
in disorders such as Huntington’s disease represents over-activity of the direct 
pathway. In addition, the basal ganglia have been implicated in a range of 
neuropsychiatric disorders, and basal ganglia function is disrupted in addictive 
states. A large series of studies has implicated the ventral striatum (including 
the nucleus accumbens), the ventral pallidum and the corresponding medial 
parts of the DA-containing cell groups of the midbrain (the ventral tegmental 
area) in the pathogenesis of schizophrenia. The fact that the prefrontal cortex is 
implicated in this disorder, and that the basal ganglia pathways linked to the 
caudate nucleus direct their outputs to prefrontal areas, raises the possibility 
that basal ganglia malfunction occurs in schizophrenia.  
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 Neurological disorders in humans can be modeled in animals using standardized 
procedures that recreate specific pathogenic events and their behavioral outcomes. 
Animals in which the nigrostriatal pathway has been experimentally destroyed are 
considered useful model for study PD [78]. These lesioned animals have clarified the 
anatomy, neurochemistry and electrophysiology of DA neurons and their 
relationships with other associated brain nuclei. 
 
Experimental Parkinson  
 PD was described by James Parkinson as a single disease entity in the year 
1817. It is a devastating neurological condition that affects at least four million 
people. Typical clinical features are extreme underactivity, poverty of 
movement (hypokinesia), infrequency of swallowing, abnormal postural 
reflexes, absence of arm swing in walking and reduced velocity of a movement 
(bradykinesia) up to inability to walk forwards (freezing). Firm and tense 
muscles (rigidity) and a low-frequency resting tremor are also seen in many 
patients, often beginning in one limb and spreading to the whole side of the 
body. A striking feature of this disorder is the preferential loss of DA-
producing neurons in the midbrain [79,80]. Several etiological triggers have 
been linked to PD, including genetic mutations and environmental toxins, but 
the pathway that leads to cell death is unknown.   
 NO was linked to PD by several lines of evidences: for instance, increased 
nNOS expression as well as tyrosine nitration in Lewy bodies in the substantia 
nigra were found in postmortem studies [81]. Levecque et al. [82] data tend to 
implicate both nNOS and iNOS genes in the development of PD. Post-mortem 
brains examination suggest that NO system in the basal ganglia is altered in 
PD [83]. NOS cell numbers and mRNA are significantly reduced in 
postmortem parkinsonian brains [81,84]. Biochemical data from human brain 
autopsy studies and from animal models point out to an ongoing oxidative 
stress process in the substantia nigra, mediated by oxygen reactive species 
(ROS) [85] which could induce degeneration of nigrostriatal DA neurons 
[86,87]. Several studies suggest that ONOO− plays an important role in the 
pathogenesis of the disease [88]. TH can be inhibited by nitrotyrosination [89]. 
Further, MAO B, whose activity increases with aging [90], is located in the 
external mitochondrial membrane and generates H2O2 during the catecholamine 
metabolism [91], possibly acting as a source of O2 −, and subsequent ONOO− 
production. Then DA neurons would be highly exposed to ONOO− damage [92]. 
Moreover, the production of NO by circulating neutrophils was enhanced by 50% 
in line with a several-fold overexpression of nNOS [93]. 
 
 In modeling experimental Parkinson a major advance was the introduction 
of the catecholamine neurotoxin 6-hydroxydopamine (6-OHDA) [94,95]. 6-
OHDA destroys DAergic neurons through free radical-mediated mechanisms. 
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Microinjection of 6-OHDA into the medial forebrain bundle can cause a total 
destruction of substantia nigra compacta and area tegmental ventral neurons 
[96] (Figure 8). It results in a well-described syndrome that includes i. near 
total depletion of DA in the ipsilateral striatum; ii. denervation supersensitivity 
of post-synaptic DA receptors in the ipsilateral striatum; and iii. a 
characteristic functional asymmetry, with quantifiable turning behavior 
contralateral to lesion side, in response to the direct DA agonist apomorphine 
[97,98]. Pavon et al. [99] report that chronic L-DOPA, the major treatment of 
PD, induces dyskinesia in hemiparkinsonian mice and induces FosB staining in 
every diaphorase-NOS-containing interneuron in the lesioned striatum. 
 
 Similarly, 1-methyl-4-pheyl-1,2,3,6- tetrahydropyridine (MPTP) and 
MPP+ induced impairment of the mitochondrial respiratory chain enhances 
superoxide formation that then can initiate apoptotic cell death through a 
decrease in mitochondrial membrane potential. MPTP, which contaminated 
batches of illicit drugs in the 1970s, produces Parkinsonian-like symptoms in 
humans [100] MPTP causes pathology by targeting the destruction of 
nigrostriatal DA neurons, the same cells that are selectively lost in idiopathic 
PD. This is accompanied by an up-regulation of iNOS gene expression in glial 
cells [101]. The majority of the studies conducted toward identifying the 
fundamental mechanism of MPP+ induced cytotoxicity in substantia nigra 
focused on cGMP independent mechanisms of NO action. These include 
oxidation of thiols as well as nitrosation and nitration of proteins. A recent 
study shows that MPP+ inhibits complex I of the mitochondrial electron  
transport chain, leads to the formation of superoxide anion and peroxinitrite 
thereby causing DNA damage, poly(ADP-ribose) polymerase (PARP I) 
activation and neuronal cell death [102]. A form of PD is caused by the production 
and accumulation of mutated cellular protein, parkin [103], and this accumulation 
results in increased nNOS activity with subsequent NO-mediated damage [102]. In 
this form of Parkinson's as well as in other forms of PD, nitrated proteins can be 
found by immunohistochemistry and immunoblotting [103]. 
 Indirect evidence implicates NO in the mechanisms underlying nigral cell 
degeneration because NOS inhibitors protect against MPTP toxicity in mice and 
monkeys (although some of these data are disputed – 104, 105]. A significant 
resistance to MPTP induced cytotoxicity was exhibited by mice lacking either 
iNOS or nNOS [104,105]. 7NI also inhibited MPTP-induced PD-like 
neuropathological changes in baboons and degeneration of the TH positive 
positive neurons in substantia nigra [106,107]. In addition, degeneration of the 
nigrostriatal pathway by malonate was prevented by LNAME and 7NI.  
 In contrast, Hunot et al. [108] found a significant increase in NADPH-d-
positive cell density in DA cell groups characterized by neuronal loss in PD. 
We showed that the number  of NADPH-d and NOS positive neurons increase 
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Figure 8. Rat brain positive neurons labeled for NADPH-d (blue) and NOS (brown) 
located in the Substantia nigra (A, B and C), striatum (D and E) and 
pedunculopontine tegmental nuclei F, G and H). Triple photomicrography (A-C), from 
the same microscopic field with distinct amplification, showing the substantia nigra pars 
compacta. The white arrow indicates the site of microinjection of the neurotoxin 6OHDA. 
There is no positive neurons for NOS and NADPH-d. D-H: Double photomicrography 
showing striatal cells from adult rat brain, stained histochemically for NADPH-d (D and 
E) and NOS (H), respectively. E is a higher magnification of A. The labeled neurons are 
striatal cells, with fewer dendritic spines, with fusiform or polygonal somata, considered 
interneurons [109]. Pedunculopontine tegmental nuclei (F, G) labeled neurons for 
NADPH-d (blue) and NOS (brown), respectively. 
 
in ipsilateral striatum and decrease in the substantia nigra after either 6-OHDA 
or electrolytic lesions of         the MFB [110]. Only in  animals that received 6-OHDA 
the number of cells decreased in contralateral nucleus accumbens. This 
evidence may raise questions regarding which brain NO containing structure is 
mainly affected on PD. Moreover, recent studies demonstrate that the activity 
of striatal NOS is depressed in 6-OHDA-lesioned animals [111,112] and 
patients with PD [81,84], indicating that agents designed to target nitrergic 
signaling may be useful for the treatment of movement disorders. Results from 
our laboratory suggest that sub-chronic administration of LNOARG partially 
protect DA neurons in 6-OHDA animals [Gomez, personal comunication]. 
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 Barthwal et al [113] described that LNAME pretreatment blocked the 
amphetamine-induced rotations and inhibited the iNOS activity at the 3rd day 
after the 6-OHDA injection and also significantly restored the striatal DA, 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid levels in 6-
OHDA treated rats. In addition, NO donors protected animals against Fe-
induced DAergic neurodegeneration. Our findings are in agreement with 
previous studies of our group [114], showing an increase in striatal NADPH-d 
neurons after lesion of substantia nigra compacta caused by manganese 
chloride. In this study, a protective role of NO was suggested since systemic 
LNOARG treatment increased apomorphine-induced rotations. In contrast, low 
concentrations of manganese, unlike other transition metals, caused induction 
of iNOS activity in astrocytes and glial cells. Glial derived neural factor which 
exerts a protective effect in PD [115], inhibits nNOS activity [116]. 
 Recently, the group of West demonstrated that striatal nNOS is stimulated 
in vivo by phasic activation of midbrain DA cells via a DA D1/5 receptor-
dependent mechanism. These findings are consistent with previous reports that 
D1/5 receptor activation increases indirect measures of NOS activity [33,117] 
and firing activity of electrophysiologically identified NOS interneurons [118]. 
D1 receptors are weakly expressed on a small number of NOS-positive 
interneurons in the striatum [119].  While D1 receptors are highly expressed in 
projection neurons, D5 receptors are mostly present in cholinergic interneurons and 
all the other types of chemically defined striatal GABAergic interneurons 
expressing parvalbumin, somatostatin or calretinin [120]. Thus, striatal NOS 
interneurons may be potently activated by DA cell burst firing in specific 
behavioural contexts. This implicates DA-induced release of NO in the control of 
motivational behavior and thus suggests novel potential therapeutic targets for the 
treatment of neurological and psychiatric disorders.  
 To summarize, there are several direct demonstrations of changes in 
neuronal NO systems following DA denervation. The data suggests that 
neuronal NO systems are regulated in response to altered input. Either NOS 
mRNA or protein appears to be differentially regulated in different basal 
ganglia structures in response to DA depletion. Such altered activity of NO-
containing neurons may play a role in the compensatory upregulation of 
nigrostriatal DA neurotransmission in PD, but might also exert an excitotoxic 
effect on striatal neurons and nigrostriatal terminals. Therefore, it seems probable 
that these changes in NOS reflect a physiological response to DA denervation 
rather than resulting from direct involvement in the pathological process of PD.  
 
Experimental schizopreny 
 The close connection between frontal cortex and the basal ganglia has provided 
support for a fundamental role of basal ganglia in schizophrenia. Interestingly, 
Graybiel [121] has proposed a concept that basal ganglia acts as “cognitive pattern 
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generators”, in that is a set of common neural circuits that regulate both motor and 
mental action. Based on this concept, Graybiel and colleagues [122] have proposed 
that similar circuitry to that used to coordination of motion sequences may be used to 
coordinate thinking, planning, and other cognitive acts.  
 Schizophrenia is a severe mental disorder, which is characterized by 
thought disturbance, abnormal perception, impaired cognition, and bizarre 
behavior. Although progress has been made during the past decade in 
identifying potential biological state and trait markers of the disease, the ideal 
indicator of schizophrenia has still not been detected. Moreover, given the 
complexity and heterogeneity of the disease, one may have doubts concerning 
its existence at all. One of the many candidates found to be linked to 
schizophrenia is NO. Historically, the first hints of a possible link between NO 
metabolism and schizophrenia can be found in two Russian papers, which dealt 
with the diagnostic value of Black's reaction (detecting methylene blue, an 
inhibitor of NOS and soluble guanylate cyclase) in psychiatric patients 
[123,124]. However, systematic research on this topic began in the early 
1990s. At that time histochemists had introduced NADPH-d histochemistry as 
a tool to label certain neuronal populations [125], and the immense importance 
of NO and its synthesizing enzyme NOS had emerged. Even at that time, the 
search for the roles of NO in schizophrenia was not restricted to the brain 
[126], but also included body fluids [127].  
 NO has been functionally linked to both DAergic and glutamatergic 
neurotransmission in the brain, both of which are strongly implicated in the 
pathophysiology of schizophrenia [39]. Figure 9 shows the proximity of nNOS 
and TH immunopositive reaction in neurons and fibers in the frontal cortex and 
amygdale giving hysthochemical support for interaction between DAergic and 
NOS neurotransmission.  Neuroanatomic studies have reported abnormal 
distributions of NOS-containing interneurons in the frontal and temporal     
lobes  of  schizophrenia  patients, suggesting        altered neuronal migration during  
development [21]. It has also been observed an increase in a correlate of NOS     
activity in the striatum of rats modeling the developmental cortical abnormalities of 
schizophrenia [128]. Remarkably, both decreases and increases in NOS activity, 
NOS protein and mRNA content were found in schizophrenia. 
 NO is increased in plasma of schizophrenic patients [22] and abnormalities 
in populations of cells containing NADPH-d [129], has been detected in these 
patients [21]. There is a low density of NADPH-d neurons in the frontal and 
temporal cortical grey and an increased density of these cells in the deep (frontal) 
or subcortical (medial temporal) white matter [21] schizophrenic patients. This 
altered distribution has been related to the diminished levels of the stable 
metabolites of NO, nitrite and nitrate, in the cerebrospinal fluid of schizophrenic 
patients [23]. In contrast, an  overproduction  of  NO found       in schizophrenic 





Figure 9. Double labeling of nNOS and TH in the Amygdala and Cerebral cortex 
of the rat brain. Confocal micrography of double-staining labeling using TH and NOS 
immunohystochemistry in the amygdala (A-C) and cerebral cortex (D) of the rat brain. 
D: Double-stained section was analyzed using fluorescence microscopy (Nikon, Japan) 
C and D are representative micrographys of the simultaneous visualization of DA and 
NO innervation in brain regions. The close proximity of nNOS(red) and TH (green) 
neurons and fibers immunopositive reaction in the frontal cortex and amygdala gives 
hysthochemical support for interaction between DAergic and NOS neurotransmission. 
 
brains, related     to an excess of  NADPH-d-positive  neurons in the mesopontine 
tegmental region, is proposed to provide critical excitatory input to the 
midbrain DA systems [130]. 
 Catalepsy test is widely used to evaluate motor effects of drugs, 
particularly those related to the extrapyramidal system [131-133]. It is defined 
as a failure to correct an externally imposed posture. Administration of DA 
antagonists, such as haloperidol, induces catalepsy in rodents [134,135] and 
Parkinson symptoms in humans [132,136]. NOS inhibitors themselves have 
antipsychotic actions [60]. Systemic injections of LNOARG and 7NI induced 
catalepsy in mice and had an additive effect with haloperidol [51,52,137,138]. 
These effects were obtained with doses commonly used in the literature 
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[49,56,139,] and were similar to those that significantly inhibit nNOS (> 10 mg 
kg-1) [140]. The cataleptic effects were detected both in the hanging-bar and in 
the wire-ring tests [51]. Figure 10 illustrate the correlation between results 
obtained in he wire-ring  and hanging-bar tests after treatment with saline or 
LNOARG. There are some studies dealing with the modification of brain NO 
synthesis by classical neuroleptics (mostly haloperidol). The observation by 
Iwahashi et al. [141] that haloperidol inhibits the activity of nNOS has been 
confirmed by others [142,143], but there are also reports showing quite the 
opposite [144]. Chlorpromazine was also shown to inhibit the activity of 
constitutive NOS [145]. Atypical neuroleptics do not influence brain levels of 
nNOS [146]. Curiously, they are capable of partly reversing haloperidol-evoked 
suppression of NOS activity, which is accompanied by a “normalization” of 
behavior in rats [142,147].  
 Chronic treatment with LNOARG increased the number of NADPH-d-
positive cells in the dorsal part of the caudate and accumbens nuclei, as 
compared to haloperidol-treated animals and in the pedunculopontine tegmental 
nucleus, as compared to saline-treated rats. In contrast, it decreases NADPH-d 
neuron number in the substantia nigra, pars compacta, an effect also found after 
chronic haloperidol treatment [47].  
 Similar to the effects obtained after systemic administration, catalepsy was 
also induced after intracerebroventricular [148], or intra-striatal injection of 
NOS inhibitors such as NG-monomethyl-L-arginine (LNMMA), 7NI, LNOARG, 
 




















Figure 10. Hanging-bar and Ring-test catalepsy test procedure: Acute treatment with 
LNOARG significantly induced catalepsy in both the hanging-bar and wire-ring test. 
Results from both tests were highly correlated (r=0.927, p<0.001). 
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LNAME in rats. The effect of i.c.v. injected LNOARG was completely 
prevented by pretreatment with L-arginine but not by D-arginine. Both i.c.v. and 
intra-striatal injection of LNOARG or LNAME produced bell-shaped dose-
response curves. These results confirm that interference with striatal formation of 
NO induces significant motor effects in rats. Spina et al. [149] failed to find any 
cataleptic effect of another NOS inhibitor LNAME (50mg/kg i.p.), in the wire 
ring test. This test was proposed by Pertwee [150] to measure immobility in 
addition to catalepsy effects produced by cannabinoids agonists. These 
contrasting results probably are related to methodological issues such as the 
interval between injection and the test and/or the dose of LNAME.  
 Both the cataleptic effect and the decrease in exploratory activity induced 
by acute doses of LNOARG suffered tolerance after 4 days of treatment and 
haloperidol [19,47,138]. The mechanism involved in this rapid tolerance 
development is unknown. Although chronic treatment with haloperidol is also 
able to induce tolerance for its catalepsy-inducing effect, it usually needs 25 
days of chronic treatment [132,151]. Accordingly, no tolerance was detected in 
our study after 4 days of haloperidol administration. Several studies have 
shown that antagonism of NMDA-mediated transmission attenuates catalepsy 
induced by DA receptor antagonists such as haloperidol [33,152]. Since 
animals that became tolerant to LNOARG are also tolerant to haloperidol 
effects, and NO has complex effects on NMDA mediated-neurotransmission, it 
is also possible that an influence of NO on DA neurotransmission is mediated 
by effects on NMDA neurotransmission.  
 We have showed that catalepsy induced by LNOARG is modulated by drugs 
that modified serotonergic neurotransmission [153]. The cataleptogenic effect of 
LNOARG was enhanced by pre-treatment with (+)-N-tert-butyl-3-(4-[2-
methoxyphenyl] piperazin-1-yl)-2-phenyl-propanamide ((+)-WAY-100135), a 5-
HT1A-selective receptor antagonist, or by ketanserin, a 5-HT2A receptor and 
α1-adrenoceptor antagonist. Prazosin, an α1-adrenoceptor antagonist, and endo - 
N - (8 - methyl - 8 - azabicyclo [3.2.1] oct - 3yl) - 2, 3- dihydro - 3, 3- dimethyl – 
indole – 1 - carboxamide HCl (BRL-46470A), a 5-HT3 receptor antagonist, did 
not interfere with LNOARG-induced catalepsy. Ritanserin, a 5-HT2a and 5-
HT2C receptor antagonist, tended to enhance the effect of LNOARG.  
 It has been reported that schizophrenic patients have a reduced level and a 
higher dietary requirement of vitamin C [154]. Also, since vitamin C /ascorbic 
acid is a potent reducing agent and can reduce haloperidol to OH-haloperidol 
whose pharmacological activity is not well established, its role in 
augmentation of haloperidol treatment of schizophrenic patients has been 
tested. In one study, it was found to work synergistically to reduce some 
psychiatric symptoms [155]. However, in an another study, shorter treatment 
(2 weeks) at a lower dose did not alter the plasma levels of haloperidol or OH-
haloperidol as well as the psychotic symptoms (Psychiatric Symptom 
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Assessment Scale), [156]. Vitamin E is a lipid soluble antioxidant and 
effective for the prevention of oxidative injury to plasma membranes. It may 
be important to use vitamin E in combination with vitamin C, a water soluble 
antioxidant [157]. There is some evidence of the efficacy of vitamin E in 
extrapyramidal disorders such as Parkinson's disease and tardive dyskinesia 
[158,159-162]. In clinical trials, vitamin E therapy is proposed to retard the 
progression of degenerative process in patients with Parkinson's disease 
[163,164]. Vitamins C and E can enhance the cataleptic effect induced by 
inhibition of NO formation or by haloperidol [165]. Treatment with vitamin C 
did not affect tolerance to LNOARG cataleptic effect induced by sub-chronic 
treatment. Vitamin E induced catalepsy by itself and, at 100 mg/kg, potentiated 
the catalepsy induced by LNOARG or Haloperidol.  
 Novel agents as Ginkgo [166] and methylene blue [60] have shown positive 
effects on general schizophrenia negative symptoms. The Ginkgo biloba extract EGb 
761 (Tebonin®, Byk Química) is a standardized mixture of active compounds, 
including flavonoid and terpenoid substances, obtained from green leaves of the 
Ginkgo biloba tree. Clinical trials support the potential therapeutic usefulness of EGb 
761 in the treatment of cerebral insufficiency [167,168], cognitive impairments [169], 
peripheral and central circulatory disease [170] and an apparent neuroprotective role 
after various neuronal insults [171]. Chronic administration of Ginkgo biloba extracts 
is proposed to improve aspects of cognitive performance. Repeated treatment with 
Gingko biloba extract EGb 761 (80 mg/kg) produced a significant increase in the 
cataleptic effect induced by both haloperidol and LNOARG. It also decreased the 
number of rearings and crossings in the open field test [172].  
 Numerous efforts have been made to develop animal paradigms of 
schizophrenia in order to mimic characteristic neurobiological and behavioral 
features of the human disease [173]. A frequently used model is the application 
of phencyclidine to rats [174], and many others. Many researchers have used 
this paradigm to study the impact of NO in experimentally evoked 
schizophrenia-like behavior. It has been shown that the administration of the 
NOS inhibitor LNAME to phencyclidine-treated rats disrupts phencyclidine-
induced behavior [175-177]. Methylene blue, an  inhibitor of  NOS  and soluble 
guanylate cyclase [178] has the same effect on the behavior of rats. 
Phencyclidine does not alter the behavior in nNOS mutant mice and in mice 
after the application of nNOS antisense [179]. Black et al. [180] have shown 
that the administration of the NOS inhibitor during brain development 
increases the sensitivity of adult animals to phencyclidine.  
 Using the postnatal lesion of the ventral hippocampus [181], Bernstein et 
al., [182] found an increase in the number of cortical nNOS/NADPH-d-
containing neurons in lesioned rats [182]. Recently, the repeated application of 
subchronic doses of the phencyclidine derivative ketamine has come into use. 
Ketamine-treated rats are characterized by a reduced cellular expression of 
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NOS/NADPH diaphorase in hippocampal neurons [183]. Interestingly, there 
was an increase in hippocampal neurogenesis in these animals [184], which 
might be connected to the reduced NO production, since NO inhibits 
neurogenesis in adult animals [185]. 
 Schizophrenia patients display deficits in sensorimotor gating, a process 
that depends on the hippocampal and DAergic inputs to the striatum [186]. 
Other behavioral abnormalities in schizophrenia, such as an exaggerated 
response to novelty or stress, have also been postulated to indicate 
malfunction of temporal corticostriatal circuits and mesolimbic DAergic 
transmission. Some of the behaviors displayed by schizophrenia patients are 
mediated by dysfunction in prefrontal and temporal cortical inputs to the 
ventral striatum, as well as connections among the amygdala, ventral 
pallidum, and limbic thalamus [187]. Prepulse inhibition (PPI) is a test that 
reflects the functioning of the sensorimotor gating and has been commonly 
used as an animal and human model of the attentional impairments seen in 
psychiatric disorders such as schizophrenia [168]. PPI is measured as a 
normal reduction of the acoustic startle response (ASR) to an intense 
stimulus (pulse) when this stimulus is immediately (30–500 ms) preceded by 
a weaker stimulus (prepulse) [188]. Whereas the ASR is controlled by brain 
structures at the level of the brainstem, the mechanism of its inhibition by the 
prepulse requires forebrain structures, such as the nucleus accumbens, 
hippocampus, amygdala and prefrontal cortex [184,189,190]. This process 
seems to be a filter of sensory input that protects the brain against an 
overflow of information. Our recent findings show that LNOARG reduces 
the ASRs and reverses the PPI disruption of rats treated systemically with 
amphetamine, an indirect DA agonist. We suggest that NO interacts with DA 
on the modulation of sensorimotor gating, probably by a presynaptic 
mechanism, since this NOS inhibitor did not affect the PPI of rats treated 
with the direct DA receptor agonists, apomorphine, bromocriptine and 
SKF38393 [24]. This interaction between NO and DA systems in the 
modulation of PPI may also underlie the attention deficit of schizophrenics. 
 
Concluding remarks  
 The NO signalling plays an important role in the integration of information 
transmitted to basal ganglia output centers via corticostriatal and striatal 
efferent pathways. The interneurons subtypes producing NO in the striatum are 
activated by the cortex during the induction phase of striatal plasticity.  
 The remarkable expansion of knowledge about the anatomy and 
physiology of the basal ganglia in recent years has encouraged the 
development of information-processing models. The motivation for 
constructing such models derives from a pressing need to interpret the growing 
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mountain of complex biological data associated with the unique neuronal 
architecture of this brain region. Some of the architectural features that are 
likely to be important are i) the existence of loops of connectivity between the 
cerebral cortex and basal ganglia; ii) the specialization of spiny neurons, the 
principal cells of the striatum, for pattern recognition computations; iii) the 
division of the striatum into matrix and patch (striossome) compartments with 
specialized neurochemistry and connectivity; and iv) the activity of midbrain DA 
neurons, which is an indispensable requisite for reinforcement learning and, 
consequently, for corticostriatal synapses plasticity. Despite the high relevance 
of NO in basal ganglia functions, so far, none of the computational models have 
attempted to simulate these effects. Considering the complexity of the functional 
dynamics of information processing within the basal ganglia and its interactions 
with the rest of the brain, quantitative models of all aspects of basal ganglia 
biology will be needed to proced further understanding of brain region.  
 In summary, we can conclude from the above studies and it is evident 
when surveying the literature that in some situations, such as normal cellular 
metabolism, NO is necessary and helpful for the cell (herein defined as 
physiological). NO-producing cells may mediate some of the actions of the 
excitatory corticostriatal afferent pathway involved in regulating the activity of 
striatal efferent and afferent systems. Yet in other situations, such as in disease, 
NO can be toxic (pathological). Considerable evidence exists indicating a role 
for NO–DA interactions in pathophysiological conditions such as Parkinson's 
disease and schizophrenia. A question to ask is why NO is helpful to the cell in 
one set of circumstances and yet a toxic agent in another set of circumstances. 
Understanding the nature of physiological NO and pathological NO is critical 
and will yield possible therapies for central nervous system disease. 
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